Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Diabetes Care · 01.10.2023 · 46 (10) · 1848-1856
DOI: 10.2337/dc23-0675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 22.08.2023. Verfasst von Kevan C Herold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Immunobiology and Internal Medicine, School of Medicine, Yale University, New Haven, CT. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Provention Bio, Inc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2 type 1 diabetes on the basis of data from the pivotal study TN-10. RESEARCH DESIGN AND METHODS To provide confirmatory evidence of the effects of teplizumab on preserving endogenous insulin production, an integrated analysis of C-peptide data from 609 patients (n = 375 patients receiving teplizumab and n = 234 control patients) from five clinical trials in stage 3 type 1 diabetes was conducted. RESULTS The primary outcome of the integrated analysis, change from baseline in stimulated C-peptide, was significantly improved at years 1 (average increase 0.08 nmol/L; P < 0.0001) and 2 (average increase 0.12 nmol/L; P < 0.0001) after one or two courses of teplizumab. An analysis of exogenous insulin use was also conducted, showing overall reductions of 0.08 (P = 0.0001) and 0.10 units/kg/day (P < 0.0001) at years 1 and 2, respectively. An integrated safety analysis of five clinical trials that enrolled 1,018 patients with stage 2 or 3 type 1 diabetes (∼1,500 patient-years of follow-up for teplizumab-treated patients) was conducted. CONCLUSIONS These data confirm consistency in the preservation of β-cell function, as measured by C-peptide, across multiple clinical trials. This analysis showed that the most common adverse events included lymphopenia, rash, and headache, a majority of which occurred during and after the first few weeks of teplizumab administration and generally resolved without intervention, consistent with a safety profile characterized by self-limited adverse events after one or two courses of teplizumab treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Immunobiology and Internal Medicine, School of Medicine, Yale University, New Haven, CT.
- Department of Pediatrics, School of Medicine, University of California San Francisco, San Francisco, CA.
- Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO.
- Provention Bio, Inc., Red Bank, NJ.
ORCID-Profile: Eleanor L Ramos
Förderung
- NCATS NIH HHS
- Provention Bio, Inc
Zitieren
APA
Herold, K. C., Gitelman, S. E., Gottlieb, P. A., Knecht, L. A., Raymond, R., & Ramos, E. L. (2023). Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care, 46(10), 1848-1856. https://doi.org/10.2337/dc23-0675
Vancouver
Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care. 2023;46(10):1848-1856. doi:10.2337/dc23-0675
BibTeX
@article{Herold2023,
author = {Herold, Kevan C and Gitelman, Stephen E and Gottlieb, Peter A and Knecht, Laura A and Raymond, Ralph and Ramos, Eleanor L},
title = {Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {10},
pages = {1848--1856},
doi = {10.2337/dc23-0675}
}
EUVIMED